What Analysts Are Saying About Teva Pharmaceutical After Earnings

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)'s highest estimates of price target are $80 and low forecast is $31 based on the opinion of 23 analysts. Deutsche Bank AG lowered their target price on Teva Pharmaceutical Industries Limited from $68.00 to $54.00 and set a buy rating for the company in a research note on Wednesday, November 16th. Finally, Oppenheimer Holdings, Inc. reissued an outperform rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, February 1st.

Shares of Teva were last seen up 2.3% at $34.80 on Tuesday, with a consensus analyst price target of $42.09 and a 52-week trading range of $31.90 to $59.35.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is now showing its ROA (Return on Assets) of 2.4%.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 33.91 on Tuesday. The company's 50-day moving average is $34.51 and its 200 day moving average is $42.93.

TEVA was trading -44.55% below its 52-week high and 0.91% above its 52-week low.

A number of analysts offered their Estimated Earnings analysis for Teva Pharmaceutical Industries Limited (NYSE:TEVA) for the current quarter.

"We are here to fix what is not working, we will leave no stone unturned", interim CEO Yitzhak Peterburg said on Monday after the company reported higher than expected fourth-quarter earnings.

Trump bashes Mark Cuban's intelligence after his warning to CEOs
Cuban said in 2015 he wouldn't run for president but called it a "fun idea to toss around". It wasn't immediately clear why Trump lashed out at Cuban, seemingly without provocation.

'Rangers man' McLeish would listen to job offer
But Warburton led Rangers' training session on Friday as well as taking part in a news conference in the morning. Candidate: Alex McLeish would find a Rangers return tough to turn down.

Bombardier gets millions from Canada for Global 7000, C Series
The company also sold a 30 per cent holding in its railway division for $1.5 billion to Quebec-based pension fund manager Caisse de dépôt.

Revenue grew 33% to $6.49 billion.

The company's net profit margin stands at -6.20% whereas its return on equity (ROE) is -12.90%. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post $5.11 EPS for the current year.

Last year, Teva, known for its generic-drugs business, closed its $40.5 billion deal for Allergan's generics operations. Analysts' estimates typically exclude special items.

This piece of content was originally reported by BBNS and is owned by of BBNS. If you are viewing this article on another publication, it was stolen and republished in violation of U.S. and global copyright & trademark legislation. The correct version of this report can be viewed at https://www.com-unik.info/2017/02/14/teva-pharmaceutical-industries-limited-teva-shares-sold-by-loudon-investment-management-llc.html.

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 20th. Stockholders of record on Thursday, March 2nd will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 4.00%. Teva Pharmaceutical Industries Limited's dividend payout ratio (DPR) is now 67.44%. Washington Trust Bank increased its position in Teva Pharmaceutical Industries Limited by 2.7% in the third quarter. Hudock Capital Group LLC boosted its position in shares of Teva Pharmaceutical Industries Limited by 37.6% in the second quarter. Washington Trust Bank now owns 2,232 shares of the company's stock valued at $103,000 after buying an additional 58 shares in the last quarter. Pillar Pacific Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 5.2% in the second quarter. Finally, Klingenstein Fields & Co. The company has a market cap of $32,673 million and the number of outstanding shares has been calculated to be 1,015,000,000 shares. Hedge funds and other institutional investors own 55.03% of the company's stock.

The Company has a global portfolio of approximately 1,000 molecules. "While we continue to manage through a turbulent and constantly evolving industry, we are committed to execute against our strategy with more diversified revenue sources and profit streams, all backed by strong product development engines in both generics and specialty".

Teva has already faced calls for management and structural changes, including a possible split into separate generic and branded medicine units.

Related news